Join to access to all OVN content. Join for Free
MSL Visibility - How to SUCCEED in 2024
Medical Science Liaisons MSL effectiveness MSL visibility MSL strategies Eleonora Goldberg

MSL Visibility - How to SUCCEED in 2024


Share This Article


Summary

Tom Caravela welcomes Eleonora Goldberg to explore the evolving role of Medical Science Liaisons (MSLs) within organizations. They delve into the key attributes leaders seek in MSLs and share strategies for standing out and enhancing team performance. Essential skills for MSL effectiveness and methods for evaluating performance are discussed, alongside preparing for industry changes and maintaining positivity in 2024. Eleonora offers predictions and expresses optimism for the future of MSLs. The episode concludes with closing remarks, appreciation, and a reminder to subscribe and stay engaged.

My guest this week is Eleonora Goldberg, Vice President, Medical Affairs at Arrowhead Pharmaceuticals and we discuss MSL Visibility and how to succeed in 2024.

 Eleonora shares….

๐Ÿ‘‰ What is the VALUE of MSLs
๐Ÿ‘‰ What leaders look for in MSLs
๐Ÿ‘‰ How can MSLs separate themselves from their peers
๐Ÿ‘‰ How might 2024 be different for MSLs
๐Ÿ‘‰ What advice is there for dealing with uncertainty

Click for Source
Medical Science Liaisons, MSL effectiveness, MSL visibility, MSL strategies, Eleonora Goldberg

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%โ€‹
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%โ€‹

Explore OVN